Elicio Therapeutics grants 21,750 options to director

ELTX granted a 21,750-share stock option to a non-employee director, vesting in 2027 and expiring in 2036, as that director’s annual equity award.

Rhea-AI Filing Summary

Elicio Therapeutics, Inc. (ELTX) reported that director Jay Venkatesan received a grant of stock options for 21,750 shares of common stock on August 31, 2026 at an exercise price of $2.70 per share. The options vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders’ meeting, subject to continued service, and expire on August 31, 2036. No additional equity award will be made to this director in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 21,750 shares

Grant/Award 1 txn

Insider Venkatesan Jay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	21,750	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,750 contracts (Direct)

Footnotes (1)

1. F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Key Figures

Stock options granted: 21,750 shares Exercise price: $2.70 per share Shares underlying options: 21,750 shares +3 more

6 metrics

Stock options granted 21,750 shares Annual non-employee director equity award granted August 31, 2026

Exercise price $2.70 per share Exercise price for the granted stock options

Shares underlying options 21,750 shares Underlying Elicio Therapeutics common stock

Post-grant option holdings (this award) 21,750 options Total derivative securities held after this reported grant

Vesting date August 31, 2027 or 2027 annual meeting Earlier of the one-year anniversary of grant or 2027 annual stockholders’ meeting

Option expiration date August 31, 2036 Expiration date of the granted stock options

Key Terms

non-employee director equity award, stock option, vesting, annual meeting of the Issuer's stockholders

4 terms

non-employee director equity award financial

"The stock option represents the annual non-employee director equity award"

stock option financial

"The stock option represents the annual non-employee director equity award"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"and shall vest and become exercisable in full on the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"the annual meeting of the Issuer's stockholders held in 2027"

FAQ

What equity award did Elicio Therapeutics (ELTX) grant to director Jay Venkatesan?

Elicio Therapeutics granted stock options for 21,750 shares of common stock to director Jay Venkatesan on August 31, 2026 as his annual non-employee director equity award.

What is the exercise price of the new ELTX stock options granted to the director?

The granted stock options have an exercise price of $2.70 per share for the underlying Elicio Therapeutics common stock.

When do the new ELTX director stock options vest?

The options vest and become exercisable in full on the earlier of August 31, 2027 or the Elicio Therapeutics 2027 annual meeting of stockholders, subject to the director continuing to provide services through the vesting date.

When do the ELTX stock options granted to the director expire?

The stock options granted to the director expire on August 31, 2036, giving a ten-year term from the date of grant.

Will the ELTX director receive another equity award at the 2026 annual meeting?

No. The filing states that no additional equity award will be made to the reporting director in connection with Elicio Therapeutics’ 2026 annual meeting of stockholders.

Were the ELTX director option grants made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported in connection with this option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:03 PM Accepted by SEC EDGAR 09/02/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venkatesan Jay

(Last) (First) (Middle)

C/O ELICIO THERAPEUTICS, INC.

451 D STREET, 5TH FLOOR, SUITE 501

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.7	08/31/2026		A		21,750		(1)	08/31/2036	Common Stock	21,750	$0	21,750	D

Explanation of Responses:

1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Megan C. Filoon, Attorney-in-fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)